Evolution of Organoid model as an alternative to animal studies

Introduction:

Cancer still remains one of the biggest challenges of our time due to its complexity, heterogeneity, drug resistance and tumour microenvironment. For decades, animal models have underpinned progress in biomedical research and still over 90% of the drugs that succeed in preclinical studies fail in human clinical trials. This has indeed called for more alternative approaches, organoids being the best replacement model mimicking the architecture and function of human organs.

Recent advancement in oncology research, coupled with updates from FDA are poised to shift the paradigm away from the traditional animal models. For TheraIndx Lifesciences, the intersection of scientific breakthroughs and regulation trends present a scientific opportunity. By developing 3D organoids in-vitro model in combination with spatial omics analytics platform, TheraIndx is becoming an ideal choice to partner with for animal-free oncology translational research, with expectations to expand in other disease areas.

Rise of 3D organoid models

3D tumour models have revolutionised cancer research and drug development by offering more physiologically relevant alternative model to 2D cell cultures. These 3D models mimic the complex tumour architecture, cell-cell interactions, making them a powerful tool for studying tumour biology, drug penetration and resistance mechanisms. As pharmaceutical companies and academic labs embrace this technology, TheraIndx aligns with their vision and offers organoids related assays to assist your research.

TheraIndx’s service offerings aligned with NAMs

AI platforms integrate genomic and transcriptomic landscapes, drug pathway networks, Clinical trial and CRISPR datasets to:

• - 3D organoids-based disease models

• - High-throughput screening

• - Mechanism of Action and biomarker studies

• - Toxicology and safety profiling

• - Integrated NAMs pipeline

• - Custom organoid development

Empowering ethical innovation- TheraIndx delivers disease-relevant and organoid driven solutions to your drug discovery projects.

References:

• 1. Kim J., Koo B-K., Knoblich J. A. “Human organoids: model systems for human biology and medicine.” Nature Reviews Molecular Cell Biology. 2020;21(10):571-584.


• 2. Ma X., et al. “Cancer organoids: A platform in basic and translational cancer research.” 2023.


• 3. Seidlitz T., et al. “Gastrointestinal cancer organoids—applications in basic cancer biology and clinical translation.” Experimental & Molecular Medicine. 2021.


• 4. “Organoids: The current status and biomedical applications.” (2023)


• 5. “Organoids | Nature Reviews Methods Primers.” (2022)